Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Severity score of pruritus ≥5 as defined by VAS
History of pruritus of >8 weeks duration.
Discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including Calmmax cream)
...
Severity score of pruritus ≥5 as defined by VAS
History of pruritus of >8 weeks duration.
Discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including Calmmax cream)
Negative pregnancy test result for all participating women of childbearing age;

Exclusion Criteria

Inability to give informed consent
Liver cirrhosis
Known allergy to Calmmax cream
...
Inability to give informed consent
Liver cirrhosis
Known allergy to Calmmax cream
Known poor adherence to medical recommendations
Decompensated heart failure
Active dermatological disorder other than UP
Any acute illness

Summary

Conditions
Calmmax Cream on UP in CKD Patients.
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Single Group Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Severity score of pruritus ≥5 as defined by VAS
History of pruritus of >8 weeks duration.
Discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including Calmmax cream)
...
Severity score of pruritus ≥5 as defined by VAS
History of pruritus of >8 weeks duration.
Discontinuation of any medication with presumed antipruritic effects at least 1 week before the study (including Calmmax cream)
Negative pregnancy test result for all participating women of childbearing age;

Exclusion Criteria

Inability to give informed consent
Liver cirrhosis
Known allergy to Calmmax cream
...
Inability to give informed consent
Liver cirrhosis
Known allergy to Calmmax cream
Known poor adherence to medical recommendations
Decompensated heart failure
Active dermatological disorder other than UP
Any acute illness

Tracking Information

NCT #
NCT02032537
Collaborators
Not Provided
Investigators
  • Principal Investigator: Itzchak Slotki, MD Shaare Zedek Medical Center
  • Itzchak Slotki, MD Shaare Zedek Medical Center